Entera Bio ENTX 深 沪
已收盘 10-09 16:00:00 美东时间
2.66
+0.160
+6.40%
华盛通- 最 高2.72
- 今 开2.51
- 成交量 158.41万股
- 最 低 2.505
- 昨 收 2.50
- 总市值 4.62亿
- 52周最高 4.20
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 0.91
- 委 比 -52.99%
- 总股本 1.74亿
- 历史最高 10.16
- 量 比 2.57
- 振 幅 8.60%
- 历史最低 0.472
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. With over 35 years of experience in global commercial leadership, Hamill joins Entera as it advances its late-stage clinical trials and prepares for the commercialization of EB613, an oral therapy for osteoporosis. Hamill previously served at Gilead Sciences and Amgen, leading multi-billion dollar franchises. Her expertise is expected ...
10-06 12:00
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Short interest data from late September 2026 highlights deeply divided investor sentiment across small-cap healthcare stocks (market capitalizations up to $2B). Heavy bearish bets remain concentrated ...
10-02 22:15
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
09-18 21:19
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Shares of Veea Inc (NASDAQ:VEEA) rose sharply in pre-market trading after the company announced a potential merger with NovaGen Group B.V. and a $10 million cornerstone investment from GeoNova Capital. Veea and NovaGen signed a term sheet to combine and are targeting execution of a definitive busine...
09-15 17:18
Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining around 100 points on Friday. Shares of Oxford Industries Inc (NYSE:OXM) fell sharply in pre-market trading after the company reported mixed second-quarter financial results. Oxford Industries reported quarterly earnings ...
09-04 20:03
Entera to Participate in Upcoming Fall Investor Conferences
Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in several fall investor conferences in 2026. The company focuses on developing oral peptide therapies for unmet medical needs using its proprietary N-Tab® technology. Its lead product, EB613, an oral PTH(1-34) tablet for osteoporosis, met Phase 2 endpoints. Entera also advances EB612 for hypoparathyroidism and other innovative therapies for obesity and rare conditions.
08-27 12:00
Entera Bio appoints new chief medical officer
The latest announcement is out from Entera Bio ( ($ENTX) ). On August 18, 2026,...
08-18 20:29
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd. has appointed Riccardo Camisasca, M.D., as its Chief Medical Officer. With over 30 years of experience in global pharmaceutical research and clinical development, Dr. Camisasca previously served as Global Head of Research & Development at Sumitomo Pharma Switzerland. His expertise will strengthen Entera’s clinical execution team and support the upcoming Phase 3 initiation of EB613, an oral anabolic treatment for osteoporosis. Dr. ...
08-18 12:00
